• Protego Biopharma will present five PROT-001 studies at the International Symposium on Amyloidosis, November 15-18, 2026.
• FDA clearance allows the Phase 2/3 SHIELD-AL study to evaluate PROT-001 added to standard care in patients with AL amyloidosis.
• Presentations include Phase 1 results in healthy volunteers evaluating the investigational lambda light chain kinetic stabilizer.
• Preclinical studies assess potential reductions in light chain-induced cardiac toxicity and compatibility with bortezomib-based treatment.
• Additional presentations cover the AmyLiteDx assay and cardiac biomarkers to support PROT-001 development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.